World Market for Precision Cancer Diagnostic Tests, a market-based and industry-focused report, examines the global market environment for precision cancer testing products and procedures, including the following data:
Market for Precision Cancer Testing, IVD and Imaging, 2018-2023
Global Precision Cancer Diagnostic Testing Product Demand by Type & Geographical Market, 2018-2023
Precision Cancer Diagnostic Testing Procedural Volume by Type, 2018-2023
Global Precision Cancer Diagnostic Testing Procedures by Type, 2018-2023
Procedures & Products
The volume of precision cancer-related procedures is projected to rise. Several trends and factors will influence growth. Advances in imaging and molecular technologies will lead to the introduction of new tests with enhanced tumor specificity and sensitivity.
The upgrading and modernization of medical delivery systems in many countries will make more funding available for cancer care. An increasing emphasis on preventive medicine in global healthcare will boost demand for tests that enable the early detection of tumors.
The report provides the following market data points:
Global Precision Cancer Diagnostic Procedural Volume, 2018-2023
Global Precision Cancer Diagnostic Product Demand, 2018-2023
Global Cancer Imaging Procedural Volume, 2018-2023
Global Cancer Imaging Product Demand, 2018-2023
Global Molecular Cancer Testing Procedural Volume, 2018-2023
Global Molecular Cancer Testing Product Demand, 2018-202
Global In Situ Hybridization (ISH) Cancer Testing Procedural Volume & Product Demand, 2018-2023
Global Blood-Based Molecular Cancer Testing Procedural Volume & Product Demand, 2018-2023
Global HPV Genotyping Cancer Testing Procedural Volume & Product Demand, 2018-2023
Global Next-Generation Sequencing (NGS) Cancer Testing Procedural Volume & Product Demand, 2018-2023
Global Mass Spectrometry (MS) Cancer Testing Procedural Volume & Product Demand, 2018-2023
Selected Mass Spectrometry-Based Oncology Tests
Global Circulating Tumor Cell Cancer Testing Procedural Volume & Product Demand, 2018-2023
Global Pharmacodiagnostic (PCD) Cancer Testing Procedural Volume & Product Demand, 2018-2023
Global Microarray Cancer Testing Procedural Volume & Product Demand, 2018-2023
Global Histology/Cytology Cancer Testing Procedural Volume, 2018-2023
Global Histology/Cytology Cancer Testing Product Demand, 2018-2023
Global Pap Test Procedural Volume & Product Demand, 2018-2023
Global Immunohistochemistry (IHC) Cancer Testing Procedural Volume & Product Demand, 2018-2023
Global Flow Cytometry Cancer Testing Procedural Volume & Product Demand, 2018-2023
Global Other Histology/Cytology (H/C) Cancer Testing Procedural Volume & Product Demand, 2018-2023
Global Tumor Marker Immunoassay Procedural Volume & Product Demand, 2018-2023
Global Tumor Marker Immunoassay Product Demand by Type, 2018-2023
Global POC Colon Cancer Testing Procedural Volume & Product Demand, 2018-2023
Geographic Markets
The size and growth potential of geographical markets for precision cancer diagnostic procedures and products vary widely from country to country due to differences in demographic patterns, lifestyles trends, health insurance coverage, healthcare spending intensity, medical delivery systems, patient care approaches, and price controls.
Based on a high level of national health expenditures and patient activity, the US market will remain the largest and most diversified. The report surveys precision cancer testing indicators for 2018 to 2023, including new cancer cases (thousand), precision cancer diagnostic procedures (million), and precision cancer diagnostic product demand (mil US$), across the following geographic markets:
United States
Canada
Mexico
Western Europe
France
Germany
Italy
Spain
United Kingdom
Other Western Europe
Asia/Pacific
Australia
China
India
Japan
Other Asia/Pacific
Brazil
Other Central & South America
Eastern Europe
Africa/Middle east
Industry Structure
The global precision cancer diagnostics segment includes approximately 300 participants, ranging in size from small, narrowly focused firms to large, diversified multinational companies. Since precision cancer diagnostics serve health care applications, they are subject to strict government regulations and serve highly price-sensitive markets.
Overall success in the industry requires an effective balancing of research and development productivity, manufacturing efficiencies, effective marketing and distribution, and responsive customer service.
World Market for Precision Cancer Diagnostic Testsexplores the activities of selected companies involved in the segment to serve as a representative sample of competitors active in the business.
The companies profiled in the report include the following:
Abbott Laboratories
Agilent Technologies, Inc.
Angle plc
Becton Dickinson and Company
Bio-Rad Laboratories, Inc.
Biocartis N.V.
Biocept, Inc.
bioMerieux SA
Canon Medical Systems Corporation
Cynvenio Biosystems, Inc.
Danaher Corporation
Epigenomics AG
Exact Sciences Corporation
Exosome Diagnostics, Inc.
Foundation Medicine, Inc.
General Electric Company
Genomic Health, Inc.
Hologic, Inc.
Illumina, Inc.
Menarini Silicon Biosystems SpA
Myriad Genetics, Inc.
NanoString Technologies, Inc.
Ortho Clinical Diagnostics
QIAGEN N.V.
Randox Laboratories Ltd.
Roche Holding AG
Royal Philips N.V.
Siemens AG
Thermo Fisher Scientific
Vela Diagnostics
Included in the demand estimates and forecasts that appear in this report are the value of reagents and other consumables employed directly in precision cancer procedures and a percentage of the value of instruments and systems purchased by end users.
This percentage reflects the portion of total IVD and imaging tests that involve cancer-related applications. The analysis covers commercially sold and distributed tests only. Laboratory-developed tests (LDTs) and tests used for research purposes are excluded from the discussion.
Key Topics Covered
1. Executive Summary
Introduction
Scope & Methodology
IVD and Imaging Markets
Product Overview
Procedure Volume
Procedural Product Costs
2. Market Environment
Overview
Macroeconomic Environment
Gross Domestic Product
Per Capita Gross Domestic Product
Demographic Trends
Population
Age Distribution
Global Healthcare Trends
National Health Expenditures
Hospitals
Physicians
Patient Activity
3. Cancer Statistics
Overview
Regional/National Trends
New Cancer Cases by Site
Lung Cancer
Breast Cancer
Colorectal Cancer
Prostate Cancer
Stomach Cancer
Liver Cancer
Esophageal Cancer
Cervical Cancer
Thyroid Cancer
Bladder Cancer
Non-Hodgkin Lymphoma
Pancreatic Cancer
Leukemia
Kidney Cancer
Uterine Cancer
Lip & Oral Cavity Cancer
Pharynx Cancer
Brain/Central Nervous System Cancer
Ovarian Cancer
Skin Melanoma
Gallbladder Cancer
Larynx Cancer
Multiple Myeloma
Other Cancers
4. Procedures & Products
Overview
Cancer Imaging
Types of Tests
Applications
Ultrasound
Computed Tomography
Magnetic Resonance Imaging
Digital Mammography
Positron Emission Tomography
Analog Mammography
Digital Breast Tomosynthesis
Molecular Breast Imaging
Other Cancer Imaging
Molecular Cancer Testing
In Situ Hybridization
Blood-Based Molecular Cancer Tests
HPV Genotyping
Next-Generation Sequencing Tests
Mass Spectrometry (MS) Tests
Circulating Tumor Cell (CTC) Tests
Pharmacodiagnostic Tests
Microarray Tests
Histology/Cytology Cancer Tests
Pap Tests
Immunohistochemistry Tests
Flow Cytometry Tests
Other Histology/Cytology Cancer Tests
Tumor Marker Immunoassays
Overview
Tumor Markers by Type
Companies
Point of Care Colorectal Cancer Tests
Ethical Tests
Over-the-Counter Tests
5. Geographic Markets
Overview
United States
Healthcare Environment
New Medicare CLFS
Value-Based Healthcare Plans
Patient Protection and Affordable Care Act
Personalized Medicine & Next-Generation Sequencing
Laboratory Developed Tests (LDTs)
Healthcare Trends
Canada
Mexico
Western Europe
France
Germany
Italy
Spain
United Kingdom
Other Western Europe
Asia/Pacific
Australia
China
India
Japan
Other Asia/Pacific
Brazil
Other Central & South America
Eastern Europe
Africa/Mideast
6. Industry Structure
Company Profiles
Abbott Laboratories (Abbott Park, Illinois, United States)
Agilent Technologies, Inc. (Santa Clara, California, United States)
Angle plc (Guildford, Surry, United Kingdom)
Becton Dickinson and Company (Franklin Lakes, New Jersey, United States)
Bio-Rad Laboratories, Inc. (Hercules, California, United States)
Biocartis N.V. (Mechelen, Belgium)
Biocept, Inc. (San Diego, California, United States)
bioMerieux SA (Marcy l'Etoile France)
Canon Medical Systems Corporation (Tochigi, Japan)
Cynvenio Biosystems, Inc. (Westlake Village, California, United States)
Danaher Corporation (Washington, D.C., United States)
Epigenomics AG (Berlin, Germany)
Exact Sciences Corporation (Madison, Wisconsin, United States)
Exosome Diagnostics, Inc. (Waltham, Massachusetts, United States)
Foundation Medicine, Inc. (Cambridge, Massachusetts, United States)
General Electric Company (Boston, Massachusetts, United States)
Genomic Health, Inc. (Redwood City, California, United States)
Hologic, Inc. (Marlborough, Massachusetts, United States)
Illumina, Inc. (San Diego, California, United States)
The heart of Vajra Coffee's natural decaffeination process lies in its adoption of the Swiss Water® Process, a natural method that removes 99% of caffeine...
United Imaging Healthcare (SSE:688271) has published its 2023 Environment, Social, and Governance (ESG) Report, reaffirming its mission to bring Equal Healthcare for All. This report highlights the company's advancements in corporate responsibility,...
United Imaging Healthcare (SSE:688271), a global leader in manufacturing advanced medical imaging and radiotherapy equipment, has released their 2023 annual report. The report reveals that the company achieved 11.41 billion CNY in revenue in 2023,...
Pierre Fabre Laboratories announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of OBGEMSAtm (vibegron under the international...
Sustain Exchange LLC is proud to announce a partnership with HearMe, a leading behavioral health peer support platform focused on ensuring healthy lives and promoting well-being. As part of this innovative partnership, SustainAble Exchange will...
C?N Diagnostics, LLC ("C2N"), a specialty diagnostics company with a vision to bring Clarity Through Innovation®, today announced a partnership agreement with Mediford Corporation, a PHC Holdings Corporation (TSE 6523) Group Company and premier...